Analyzing Biotricity (OTCMKTS:BTCY) and 10x Genomics (NASDAQ:TXG)

10x Genomics (NASDAQ:TXG) and Biotricity (OTCMKTS:BTCY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Valuation and Earnings

This table compares 10x Genomics and Biotricity”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82 million	3.75	-$43.54 million	($0.35)	-53.97
Biotricity	$13.79 million	0.53	-$8.42 million	($0.16)	-1.61

Biotricity has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for 10x Genomics and Biotricity, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	3	9	4	0	2.06
Biotricity	0	0	0	0	0.00

10x Genomics currently has a consensus price target of $18.11, indicating a potential downside of 4.14%. Given 10x Genomics’ stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Biotricity.

Insider & Institutional Ownership

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Comparatively, 10.1% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares 10x Genomics and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
10x Genomics	-6.77%	-6.89%	-5.34%
Biotricity	-25.99%	N/A	-67.82%

Risk and Volatility

10x Genomics has a beta of 2.24, meaning that its share price is 124% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

Summary

10x Genomics beats Biotricity on 9 of the 14 factors compared between the two stocks.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.